Skip to content

Study · Animal study (in vivo) · mouse · 2018

8 results

Melanotan II causes hypothermia in mice by activation of mast cells and stimulation of histamine 1 receptors.

Jain S, Panyutin A, Liu N, Xiao C, Piñol RA, Pundir P, Girardet C, Butler AA, Dong X, Gavrilova O, Reitman ML

American journal of physiology. Endocrinology and metabolism29 May 2018Cited by 13 (Europe PMC)

PMID29812984 (opens in a new tab)PMCIDPMC6171009 (opens in a new tab)DOI10.1152/ajpendo.00024.2018 (opens in a new tab)PepBankPUB-29812984
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Other

    In mice, intraperitoneal MTII caused a profound, transient hypometabolism and hypothermia.

    In plain wordsIn mice, MTII injected into the belly cavity caused a deep but short drop in body temperature.

    Peptide
    Melanotan II
    Outcome
    DecreaseHypothermia and hypometabolism
    Study

    mousen: not reported in source

    Outcome group
    Body temperature · Whole body
    Studied dose
    Dose not stated · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Intraperitoneal administration of the melanocortin agonist melanotan II (MTII) to mice causes a profound, transient hypometabolism/hypothermia.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mast cell-deficient mice, MTII-induced hypothermia was abolished, so mast cells are required for the effect.

    In plain wordsIn mice without mast cells, MTII did not cause the drop in body temperature.

    Peptide
    Melanotan II
    Outcome
    No significant changeMTII-induced hypothermia in mast cell-deficient mice
    Study

    mousen: not reported in source

    Kit W-sh/W-sh mice (no mast cells)
    Outcome group
    Body temperature · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Here we show that MTII-induced hypothermia was abolished in KitW-sh/W-sh mice, which lack mast cells, demonstrating that mast cells are required.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In MRGPRB2-null mice, MTII-induced hypothermia was intact.

    In plain wordsIn mice lacking the MRGPRB2 receptor, MTII still caused the drop in body temperature.

    Peptide
    Melanotan II
    Outcome
    DecreaseMTII-induced hypothermia in MRGPRB2-null mice
    Study

    mousen: not reported in source

    MRGPRB2-null mice
    Outcome group
    Body temperature · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MTII-induced hypothermia was intact in MRGPRB2-null mice.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In wild-type and MRGPRB2-null mice, MTII treatment increased plasma histamine levels.

    In plain wordsIn mice, MTII raised histamine levels in the blood.

    Peptide
    Melanotan II
    Outcome
    IncreasePlasma histamine in wild-type and MRGPRB2-null mice
    Study

    mousen: not reported in source

    wild-type and MRGPRB2-null mice
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Confirming that MTII activated mast cells, MTII treatment increased plasma histamine levels in both wild-type and MRGPRB2-null, but not in KitW-sh/W-sh, mice.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mast cell-deficient mice, MTII treatment did not increase plasma histamine.

    In plain wordsIn mice without mast cells, MTII did not raise histamine levels in the blood.

    Peptide
    Melanotan II
    Outcome
    No significant changePlasma histamine in mast cell-deficient mice
    Study

    mousen: not reported in source

    Kit W-sh/W-sh mice (no mast cells)
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Confirming that MTII activated mast cells, MTII treatment increased plasma histamine levels in both wild-type and MRGPRB2-null, but not in KitW-sh/W-sh, mice.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In mice, the selective H1 antagonist pyrilamine greatly diminished MTII-induced hypothermia, so histamine acts through H1 receptors.

    In plain wordsIn mice, blocking the histamine H1 receptor with pyrilamine greatly reduced the MTII-induced drop in body temperature.

    Peptide
    Melanotan II
    Outcome
    Not applicableMTII hypothermia with H1 antagonist pyrilamine
    Study

    mousen: not reported in source

    Outcome group
    Body temperature · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The released histamine produced hypothermia via histamine H1 receptors because either a selective antagonist, pyrilamine, or ablation of H1 receptors greatly diminished the hypothermia.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In mice lacking H1 receptors, MTII-induced hypothermia was greatly diminished.

    In plain wordsIn mice without histamine H1 receptors, the MTII-induced drop in body temperature was much smaller.

    Peptide
    Melanotan II
    Outcome
    Not applicableMTII hypothermia with H1 receptor ablation
    Study

    mousen: not reported in source

    H1 receptor-ablated mice
    Outcome group
    Body temperature · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The released histamine produced hypothermia via histamine H1 receptors because either a selective antagonist, pyrilamine, or ablation of H1 receptors greatly diminished the hypothermia.
  8. 08LabIn vitro (cells)Mechanism

    In vitro, MTII stimulated mast cells through both MRGPRB2-dependent and MRGPRB2-independent mechanisms.

    In plain wordsIn cells, MTII activated mast cells in two ways, one through the MRGPRB2 receptor and one without it.

    Peptide
    Melanotan II
    Outcome
    IncreaseMast cell stimulation in vitro
    Study

    n: not reported in source

    mast cells
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro, MTII stimulated mast cells by both MRGPRB2-dependent and -independent mechanisms

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.